share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

CRISPR Therapeutics | 4：持股變動聲明-高管 KASINGER JAMES R.
美股SEC公告 ·  10/19 05:39

牛牛AI助理已提取核心訊息

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on October 16, 2024. However, the announcement did not disclose the type of action, status, number of shares involved, nature of the shares, transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on October 16, 2024. However, the announcement did not disclose the type of action, status, number of shares involved, nature of the shares, transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
CRISPR Therapeutics的總法律顧問兼秘書James R. Kasinger據報道參與了一筆涉及公司股票的交易。該行動發生在2024年10月16日。然而，公告未披露行動類型、狀態、涉及股數、股權性質、交易價格或交易後參股金融詳情。沒有這些具體信息，此事件對CRISPR Therapeutics股票的影響對投資者而言仍不明確。
CRISPR Therapeutics的總法律顧問兼秘書James R. Kasinger據報道參與了一筆涉及公司股票的交易。該行動發生在2024年10月16日。然而，公告未披露行動類型、狀態、涉及股數、股權性質、交易價格或交易後參股金融詳情。沒有這些具體信息，此事件對CRISPR Therapeutics股票的影響對投資者而言仍不明確。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間